Patents by Inventor Ana María Perez Castillo

Ana María Perez Castillo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS
    Publication number: 20230330063
    Abstract: Combination product for the treatment of neurological and/or psychiatric disorders The present application provides a combination product for the treatment and/or prevention of psychiatric and/or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and/or psychedelic side effects, and (ii) a 5-HT2A receptor antagonist which alleviates and/or removes the hallucinogenic and/or psychedelic side effects caused by the first compound.
    Type: Application
    Filed: June 21, 2023
    Publication date: October 19, 2023
    Inventors: Ana Maria Perez Castillo, Jordi Riba Serrano, Jose Angel Morales Garcia
  • Combination product for the treatment of neurological and/or psychiatric disorders
    Patent number: 11723894
    Abstract: The present application provides a combination product for the treatment and/or prevention of psychiatric and/or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and/or psychedelic side effects, and (ii) a 5-HT2A receptor antagonist which alleviates and/or removes the hallucinogenic and/or psychedelic side effects caused by the first compound.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: August 15, 2023
    Assignee: TERRAN BIOSCIENCES, INC.
    Inventors: Ana Maria Perez Castillo, Jordi Riba Serrano, Jose Ángel Morales García
  • COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS
    Publication number: 20200397752
    Abstract: The present application provides a combination product for the treatment and/or prevention of psychiatric and/or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and/or psychedelic side effects, and (ii) a 5-HT2A receptor antagonist which alleviates and/or removes the hallucinogenic and/or psychedelic side effects caused by the first compound.
    Type: Application
    Filed: October 26, 2018
    Publication date: December 24, 2020
    Applicants: Consejo Superior de Investigacions Cientificas (CSIS), Universidad Autonoma de Madrid, Centro de Investigacion Biomedica en Red de Enformedadas Neurodegerativas, Blumentech, S.L., Institute de Recerca de L'Hospital de la Santa Creu I Sant Pau
    Inventors: Ana Maria Perez Castillo, Jordi Riba Serra-No, Jose Angel Morales Garcia
  • Substituted 5-imino-1,2,4-thiadiazoles that can be used to treat neurodegenerative diseases
    Patent number: 9604947
    Abstract: The present invention is based on the use of a broad family of 5-imino-1,2,4-thiadiazoles as potential new drugs for the treatment of diseases in which PDE7 inhibition is important, specially inflammatory diseases, autoimmune and neurodegenerative disorders. On the other hand, compounds of the 5-imino-1,2,4-thiadiazole family are here described, as well as their synthetic procedures, and they may have great application as drug or drug candidates.
    Type: Grant
    Filed: October 4, 2010
    Date of Patent: March 28, 2017
    Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
    Inventors: Ana Martínez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Daniel Perez Fernandez, Concepción Perez Martín, Ana María Perez Castillo, María Isabel Loza Garcia, María Isabel Cadavid Torres, José Brea Floriani
  • SUBSTITUTED 5-IMINO-1,2,4-THIADIAZOLES THAT CAN BE USED TO TREAT NEURODEGENERATIVE DISEASES
    Publication number: 20120225879
    Abstract: The present invention is based on the use of a broad family of 5-imino-1,2,4-thiadiazoles as potential new drugs for the treatment of diseases in which PDE7 inhibition is important, specially inflammatory diseases, autoimmune and neurodegenerative disorders. On the other hand, compounds of the 5-imino-1,2,4-thiadiazole family are here described, as well as their synthetic procedures, and they may have great application as drug or drug candidates.
    Type: Application
    Filed: October 4, 2010
    Publication date: September 6, 2012
    Applicant: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFACAS ( CSIC)
    Inventors: Ana Martínez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Daniel Perez Fernandez, Concepción Perez Martín, Ana María Perez Castillo, María Isabel Loza Garcia, María Isabe Cadavid Torres, José Brea Floriani